FI90254B - Dynamisk enzymreaktor med kontinuerlig flöde - Google Patents
Dynamisk enzymreaktor med kontinuerlig flöde Download PDFInfo
- Publication number
- FI90254B FI90254B FI894472A FI894472A FI90254B FI 90254 B FI90254 B FI 90254B FI 894472 A FI894472 A FI 894472A FI 894472 A FI894472 A FI 894472A FI 90254 B FI90254 B FI 90254B
- Authority
- FI
- Finland
- Prior art keywords
- factor
- enzyme
- enzyme reactor
- phospholipid
- blood coagulation
- Prior art date
Links
- 108090000790 Enzymes Proteins 0.000 title claims description 67
- 102000004190 Enzymes Human genes 0.000 title claims description 67
- 229940088598 enzyme Drugs 0.000 claims description 66
- 108010023321 Factor VII Proteins 0.000 claims description 48
- 229940012413 factor vii Drugs 0.000 claims description 48
- 102100023804 Coagulation factor VII Human genes 0.000 claims description 47
- 108010000499 Thromboplastin Proteins 0.000 claims description 44
- 102000002262 Thromboplastin Human genes 0.000 claims description 44
- 150000003904 phospholipids Chemical class 0.000 claims description 39
- 238000000034 method Methods 0.000 claims description 31
- 102000015081 Blood Coagulation Factors Human genes 0.000 claims description 27
- 108010039209 Blood Coagulation Factors Proteins 0.000 claims description 27
- 239000003114 blood coagulation factor Substances 0.000 claims description 26
- 108010014173 Factor X Proteins 0.000 claims description 24
- 239000012528 membrane Substances 0.000 claims description 23
- 108010054265 Factor VIIa Proteins 0.000 claims description 21
- 229940012414 factor viia Drugs 0.000 claims description 21
- 239000000047 product Substances 0.000 claims description 18
- 102100022641 Coagulation factor IX Human genes 0.000 claims description 16
- 108010076282 Factor IX Proteins 0.000 claims description 16
- 229960004222 factor ix Drugs 0.000 claims description 15
- 238000006911 enzymatic reaction Methods 0.000 claims description 14
- 238000006243 chemical reaction Methods 0.000 claims description 13
- 239000003153 chemical reaction reagent Substances 0.000 claims description 12
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 claims description 11
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 claims description 11
- 229940019700 blood coagulation factors Drugs 0.000 claims description 11
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 claims description 9
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 claims description 7
- 102100027378 Prothrombin Human genes 0.000 claims description 7
- 229910001424 calcium ion Inorganic materials 0.000 claims description 7
- 230000001419 dependent effect Effects 0.000 claims description 7
- 238000005259 measurement Methods 0.000 claims description 7
- 229940039716 prothrombin Drugs 0.000 claims description 7
- 108010094028 Prothrombin Proteins 0.000 claims description 6
- 239000000203 mixture Substances 0.000 claims description 6
- 230000002255 enzymatic effect Effects 0.000 claims description 5
- 239000007788 liquid Substances 0.000 claims description 5
- 108010014172 Factor V Proteins 0.000 claims description 4
- 102000001690 Factor VIII Human genes 0.000 claims description 4
- 108010054218 Factor VIII Proteins 0.000 claims description 4
- 238000004458 analytical method Methods 0.000 claims description 4
- 238000003556 assay Methods 0.000 claims description 4
- 229960000301 factor viii Drugs 0.000 claims description 4
- 239000003593 chromogenic compound Substances 0.000 claims description 3
- 230000008569 process Effects 0.000 claims description 3
- 230000002378 acidificating effect Effects 0.000 claims description 2
- 239000007795 chemical reaction product Substances 0.000 claims description 2
- 238000005086 pumping Methods 0.000 claims description 2
- 241000257303 Hymenoptera Species 0.000 claims 1
- 239000007850 fluorescent dye Substances 0.000 claims 1
- UPSFMJHZUCSEHU-JYGUBCOQSA-N n-[(2s,3r,4r,5s,6r)-2-[(2r,3s,4r,5r,6s)-5-acetamido-4-hydroxy-2-(hydroxymethyl)-6-(4-methyl-2-oxochromen-7-yl)oxyoxan-3-yl]oxy-4,5-dihydroxy-6-(hydroxymethyl)oxan-3-yl]acetamide Chemical compound CC(=O)N[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@H]1[C@H](O)[C@@H](NC(C)=O)[C@H](OC=2C=C3OC(=O)C=C(C)C3=CC=2)O[C@@H]1CO UPSFMJHZUCSEHU-JYGUBCOQSA-N 0.000 claims 1
- 230000007935 neutral effect Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 description 24
- 230000015271 coagulation Effects 0.000 description 20
- 238000005345 coagulation Methods 0.000 description 20
- 108010062466 Enzyme Precursors Proteins 0.000 description 18
- 102000010911 Enzyme Precursors Human genes 0.000 description 18
- 230000000694 effects Effects 0.000 description 18
- 229940012426 factor x Drugs 0.000 description 18
- 108010074860 Factor Xa Proteins 0.000 description 17
- 210000002381 plasma Anatomy 0.000 description 14
- 239000000243 solution Substances 0.000 description 11
- 108010048049 Factor IXa Proteins 0.000 description 9
- 210000004369 blood Anatomy 0.000 description 9
- 239000008280 blood Substances 0.000 description 9
- 230000004913 activation Effects 0.000 description 8
- 230000023555 blood coagulation Effects 0.000 description 8
- 206010053567 Coagulopathies Diseases 0.000 description 7
- 108090000190 Thrombin Proteins 0.000 description 7
- 230000035602 clotting Effects 0.000 description 7
- 102000004169 proteins and genes Human genes 0.000 description 7
- 108090000623 proteins and genes Proteins 0.000 description 7
- 230000003068 static effect Effects 0.000 description 7
- 229960004072 thrombin Drugs 0.000 description 7
- 208000032843 Hemorrhage Diseases 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 208000034158 bleeding Diseases 0.000 description 6
- 230000000740 bleeding effect Effects 0.000 description 6
- MUCZHBLJLSDCSD-UHFFFAOYSA-N diisopropyl fluorophosphate Chemical compound CC(C)OP(F)(=O)OC(C)C MUCZHBLJLSDCSD-UHFFFAOYSA-N 0.000 description 6
- 229960005051 fluostigmine Drugs 0.000 description 6
- 108010071808 prepro-factor VII Proteins 0.000 description 6
- 241000283690 Bos taurus Species 0.000 description 5
- 239000003146 anticoagulant agent Substances 0.000 description 5
- 229940127219 anticoagulant drug Drugs 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 239000012530 fluid Substances 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 4
- 208000007536 Thrombosis Diseases 0.000 description 4
- 239000003599 detergent Substances 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 230000003993 interaction Effects 0.000 description 4
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- 239000007995 HEPES buffer Substances 0.000 description 3
- 108020004511 Recombinant DNA Proteins 0.000 description 3
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 3
- 229930003448 Vitamin K Natural products 0.000 description 3
- 239000003012 bilayer membrane Substances 0.000 description 3
- 229940098773 bovine serum albumin Drugs 0.000 description 3
- 238000010367 cloning Methods 0.000 description 3
- 239000008367 deionised water Substances 0.000 description 3
- 229910021641 deionized water Inorganic materials 0.000 description 3
- 201000007386 factor VII deficiency Diseases 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- HEGSGKPQLMEBJL-RKQHYHRCSA-N octyl beta-D-glucopyranoside Chemical compound CCCCCCCCO[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HEGSGKPQLMEBJL-RKQHYHRCSA-N 0.000 description 3
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- -1 production Proteins 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 238000011282 treatment Methods 0.000 description 3
- 229910052722 tritium Inorganic materials 0.000 description 3
- 235000019168 vitamin K Nutrition 0.000 description 3
- 239000011712 vitamin K Substances 0.000 description 3
- 150000003721 vitamin K derivatives Chemical class 0.000 description 3
- 229940046010 vitamin k Drugs 0.000 description 3
- KQJTXYQXRHCWKW-PJSBSAQXSA-N (4s)-4-[[(2s,3s)-2-benzamido-3-methylpentanoyl]amino]-5-[[2-[[(2s)-5-(diaminomethylideneamino)-1-(4-nitroanilino)-1-oxopentan-2-yl]amino]-2-oxoethyl]amino]-5-oxopentanoic acid;hydrochloride Chemical compound Cl.N([C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CCCN=C(N)N)C(=O)NC=1C=CC(=CC=1)[N+]([O-])=O)C(=O)C1=CC=CC=C1 KQJTXYQXRHCWKW-PJSBSAQXSA-N 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 229920004890 Triton X-100 Polymers 0.000 description 2
- 239000013504 Triton X-100 Substances 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 238000009835 boiling Methods 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 238000009792 diffusion process Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 2
- 230000004089 microcirculation Effects 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 210000001616 monocyte Anatomy 0.000 description 2
- 208000010125 myocardial infarction Diseases 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 230000002797 proteolythic effect Effects 0.000 description 2
- 230000009257 reactivity Effects 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 230000001960 triggered effect Effects 0.000 description 2
- 230000002792 vascular Effects 0.000 description 2
- YDMBNDUHUNWWRP-VJBWXMMDSA-N (2s)-1-[(2r)-2-amino-3-phenylpropanoyl]-n-[(2s)-5-(diaminomethylideneamino)-1-(4-nitroanilino)-1-oxopentan-2-yl]piperidine-2-carboxamide Chemical compound C([C@@H](N)C(=O)N1[C@@H](CCCC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NC=1C=CC(=CC=1)[N+]([O-])=O)C1=CC=CC=C1 YDMBNDUHUNWWRP-VJBWXMMDSA-N 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- QYLJIYOGHRGUIH-CIUDSAMLSA-N Arg-Ile Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)[C@@H](N)CCCNC(N)=N QYLJIYOGHRGUIH-CIUDSAMLSA-N 0.000 description 1
- 206010008111 Cerebral haemorrhage Diseases 0.000 description 1
- 102100037529 Coagulation factor V Human genes 0.000 description 1
- 102100029117 Coagulation factor X Human genes 0.000 description 1
- 208000037487 Endotoxemia Diseases 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- 101000635804 Homo sapiens Tissue factor Proteins 0.000 description 1
- 102000000589 Interleukin-1 Human genes 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 101710141452 Major surface glycoprotein G Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 208000002787 Pregnancy Complications Diseases 0.000 description 1
- 208000010378 Pulmonary Embolism Diseases 0.000 description 1
- 108010039286 S 2238 Proteins 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- 108010022999 Serine Proteases Proteins 0.000 description 1
- 102000012479 Serine Proteases Human genes 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 108010031969 benzoyl-Ile-Glu-Gly-Arg-p-nitroanilide Proteins 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 239000005388 borosilicate glass Substances 0.000 description 1
- BULLHNJGPPOUOX-UHFFFAOYSA-N chloroacetone Chemical compound CC(=O)CCl BULLHNJGPPOUOX-UHFFFAOYSA-N 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 230000009852 coagulant defect Effects 0.000 description 1
- 238000010668 complexation reaction Methods 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 229940125532 enzyme inhibitor Drugs 0.000 description 1
- 239000002532 enzyme inhibitor Substances 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- 238000012921 fluorescence analysis Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 229940099816 human factor vii Drugs 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 238000005567 liquid scintillation counting Methods 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 230000003169 placental effect Effects 0.000 description 1
- 230000020971 positive regulation of blood coagulation Effects 0.000 description 1
- 230000031915 positive regulation of coagulation Effects 0.000 description 1
- 208000012113 pregnancy disease Diseases 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000000164 protein isolation Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 238000003345 scintillation counting Methods 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000012536 storage buffer Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 239000010409 thin film Substances 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 210000005166 vasculature Anatomy 0.000 description 1
- 238000003260 vortexing Methods 0.000 description 1
- 229960005080 warfarin Drugs 0.000 description 1
- PJVWKTKQMONHTI-UHFFFAOYSA-N warfarin Chemical compound OC=1C2=CC=CC=C2OC(=O)C=1C(CC(=O)C)C1=CC=CC=C1 PJVWKTKQMONHTI-UHFFFAOYSA-N 0.000 description 1
- 150000008495 β-glucosides Chemical class 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
- C12M21/00—Bioreactors or fermenters specially adapted for specific uses
- C12M21/18—Apparatus specially designed for the use of free, immobilized or carrier-bound enzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
- C12M23/00—Constructional details, e.g. recesses, hinges
- C12M23/02—Form or structure of the vessel
- C12M23/06—Tubular
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/56—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving blood clotting factors, e.g. involving thrombin, thromboplastin, fibrinogen
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/914—Hydrolases (3)
- G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
- G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
- G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
- G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
- G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
- G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
- G01N2333/96433—Serine endopeptidases (3.4.21)
- G01N2333/96441—Serine endopeptidases (3.4.21) with definite EC number
- G01N2333/96444—Factor X (3.4.21.6)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/914—Hydrolases (3)
- G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
- G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
- G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
- G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
- G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
- G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
- G01N2333/96433—Serine endopeptidases (3.4.21)
- G01N2333/96441—Serine endopeptidases (3.4.21) with definite EC number
- G01N2333/96447—Factor VII (3.4.21.21)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/914—Hydrolases (3)
- G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
- G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
- G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
- G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
- G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
- G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
- G01N2333/96433—Serine endopeptidases (3.4.21)
- G01N2333/96441—Serine endopeptidases (3.4.21) with definite EC number
- G01N2333/96463—Blood coagulation factors not provided for in a preceding group or according to more than one of the proceeding groups
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/914—Hydrolases (3)
- G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
- G01N2333/974—Thrombin
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2405/00—Assays, e.g. immunoassays or enzyme assays, involving lipids
- G01N2405/04—Phospholipids, i.e. phosphoglycerides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Wood Science & Technology (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Sustainable Development (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Neurosurgery (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Clinical Laboratory Science (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Claims (23)
1. En dynamisk enzymreaktor med kontinuerligt flöde för att utföra och analysera enzymatiska fosfolipidberoende reaktio- * ner, kännetecknad av att, den innefattar en rör- formig del vars inneryta är betäckt med en plan fosfolipiddub-belmembran, varvid höljet är anslutningsbart genom en av dess öppningar till en anordning för inmatande av flytande reagens-ser och genom sin andra öppning till en anordning för uppsam-ling och analys av utströmmande vätska.
2. En enzymreaktor enligt patentkravet 1, känne-tecknad av att, höljet utgörs av ett kapillärrör.
3. En enzymreaktor enligt patentkraven 1-2, kännetecknad av att, höljet är ett kapillärrör, vars inre diameter är ca 0,1 - 1,1 mm och längden ca 1,0 - 15 cm.
4. En enzymreaktor enligt patentkravet 1, kännetecknad av att, fosfolipidmembranen innefattar ätmins-tone en ytterligare komponent utvald ur gruppen, enzymer och enzymkofaktorer
5. En enzymreaktor enligt patentkravet 4, kännetecknad av att, kofaktoren är en vävnadsfaktor.
6. En enzymreaktor enligt patentkravet 1, kännetecknad av att, fosfolipidmembranen innehäller neutrala och sura fosfolipider.
7. En enzymreaktor enligt patentkravet 1, kännetecknad av att, fosfolipidmembranen innehäller fosfa-tidylkolin och fosfatidylserin. 1 En enzymreaktor enligt patentkravet 1, kännetecknad av att, fosfolipidmembranen bestär av en bland-ning av 60 - 100 % fosfatidylkolin och 0 - 40 % fosfatidylserin. 22 90254
9. En enzymreaktor enligt patentkravet 1, kanne-tecknad av att, fosfolipidmembranen bestir av en bland-ning av 70 % fosfatidylkolin och 30 % fosfatidylserin.
10. En enzymreaktor enligt patentkravet 5, k ä n n e -tecknat av att, fosfolipidmembranen innehiller vävnads-faktor i ett förhillande av ca 1 - 10 mol vävnadsfaktor per 100 000 mol fosfolipid.
11. Ett förfarande för kontinuerlig utförande och mätande av dynamiska enzymreaktioner, kännetecknat av att, det innefattar: (a) inmatning av reagenser för utförande av en enzymatisk reaktion med en bestämd flödeshastighet tili inloppet av en dy-namisk enzymreaktor med kontinuerligt flöde, varvid reaktorn bestir av en rörformig del, vars inre yta är betäckt med en pian fosfolipiddubbelmembran, varvid reagenserna och membran-komponenterna är separat inaktiva för utförande av den enzyma-tiska reaktionen , men tillsammans ger ett aktivt enzymatiskt system; (b) pumpning av reagenserna genom enzymreaktorn med en kons-tant och bestämd f lödeshastighet si att en enzymreaktion sker i enzymreaktorn di reagenserna kommer i kontakt med fosfolipidmembranen . (c) uppsamling av enzymreaktionens produkt i den frin enzymreaktorn utströmmande vätskan; och (d) mätning av den i enzymreaktionen bildade produktens hait med lämpliga analysmetoder.
12. Ett förfarande enligt patentkravet 11, kännetecknat av att, fosfolipidmembranen innefattar itmins-tone en ytterligare komponent utvald ur gruppen, enzymer och enzymekofaktorer. \ 23 90254
13. Ett förfarande enligt patentkravet 12, kanne-tecknat av att, kofaktorn är en vävnadsfaktor.
14. Ett förfarande enligt patentkravet 13, kanne- , tecknat av att, reagenserna innefattar blodkoagule- ringsfaktorer och kalciumjoner.
15. Ett förfarande enligt patentkravet 14, känne-tecknat av att, blodkoaguleringsfaktorerna innefattar en blodkoaguleringsfaktor utvald ur gruppen, faktor VII och faktor VIIa, tillsammans med ätminstone en faktor utvald ur gruppen, faktor IX, faktor X, faktor V, faktor VIII, protrom-bin och helplasma.
16. Ett förfarande enligt patentkravet 14, känne-tecknat av att, blodkoaguleringsfaktorerna är faktor VII och faktor IX:
17. Ett förfarande enligt patentkravet 14, känne-tecknat av att, blodkoaguleringsfaktorerna är faktorn VII, och faktorn IX.
18. Ett förfarande enligt patentkravet 14, k ä n n e -tecknat av att, blodkoaguleringsfaktorerna är faktorn VII och X.
19. Ett förfarande enligt patentkravet 14, kanne-tecknat av att, blodkoaguleringsfaktorerna är faktorn VII, och faktorn X.
20. Ett förfarande enligt patentkravet 14, känne-tecknat av att blodkoaguleringsfaktorerna är faktorn VII, faktorn X, faktorn V och protrombin.
21. Ett förfarande enligt patentkravet 14, kanne-tecknat av att, blodkoaguleringsfaktorerna är faktorn VII,, faktorn X, faktorn V och protrombin. \ 24 90254
22. Ett förfarande enligt patentkravet 11, kanne-tecknat av att, analysmetoden för mätning av produkt-halten är utvald ur gruppen, bestr&lningsmätningar, kromogena mätningar och fluorogena mätningar.
23. Ett förfarande enligt patentkravet 11, känne-tecknat av att, det ytterligare innefattar tillsatsen av kromogeniskt eller fluorogeniskt substrat soin är specifikt för reaktionsprodukten, tili den utflödande vätskan innan mätning av den bildade produktens hait.
24. Ett förfarande enligt patentkravet 11, kanne-tecknat av att, det ytterligare innefattar den frän enzymreaktorn utflödande produktströmmens uppdelning sk att man kan mätä flera än en produkt bildad i enzymreaktorn.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US15408388 | 1988-02-08 | ||
| US07/154,083 US4865984A (en) | 1988-02-08 | 1988-02-08 | Dynamic continuous flow enzyme reactor |
| PCT/US1989/000397 WO1989007133A2 (en) | 1988-02-08 | 1989-02-01 | Dynamic continuous flow enzyme reactor |
| US8900397 | 1989-02-01 |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| FI894472A0 FI894472A0 (sv) | 1989-09-21 |
| FI894472A FI894472A (sv) | 1989-09-21 |
| FI90254B true FI90254B (sv) | 1993-09-30 |
| FI90254C FI90254C (sv) | 1994-01-10 |
Family
ID=22549933
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FI894472A FI90254C (sv) | 1988-02-08 | 1989-09-21 | Dynamisk enzymreaktor med kontinuerlig flöde |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US4865984A (sv) |
| EP (1) | EP0353291B1 (sv) |
| JP (1) | JP2756606B2 (sv) |
| AU (1) | AU607661B2 (sv) |
| CA (1) | CA1282361C (sv) |
| DK (1) | DK494989A (sv) |
| FI (1) | FI90254C (sv) |
| WO (1) | WO1989007133A2 (sv) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5045479A (en) * | 1988-07-05 | 1991-09-03 | The Johns Hopkins University | Continuous flow competitive assay with reference system |
| GB9022938D0 (en) * | 1990-10-22 | 1990-12-05 | Biocompatibles Ltd | Non-thrombogenic surfaces |
| US6203816B1 (en) * | 1990-11-13 | 2001-03-20 | Corvas International, Inc. | Tissue factor based prothrombin time reagent |
| US5314695A (en) † | 1990-11-13 | 1994-05-24 | Corvas International, Inc. | Tissue factor based prothrombin time reagent |
| DE69224622T2 (de) * | 1991-10-04 | 1998-11-05 | Dade Behring, Inc., Deerfield, Ill. | Herstellung von prothrombinzeit-reagenzien aus rekombinantem menschlichem gewebefaktor und sythetischen phospholipiden |
| US6114135A (en) * | 1991-11-08 | 2000-09-05 | Goldstein; Sheldon | Multiple coagulation test system and method of using a multiple coagulation test system |
| US5366869A (en) * | 1991-11-08 | 1994-11-22 | Sheldon Goldstein | Multiple coagulation test device and method |
| EP0706658B1 (en) * | 1994-04-28 | 2001-06-27 | Dade Behring Inc. | Calibrator for prothrombin time (pt) assays |
| US5731212A (en) * | 1994-12-20 | 1998-03-24 | International Technidyne Corporation | Test apparatus and method for testing cuvette accommodated samples |
| US20030232075A1 (en) * | 2002-05-06 | 2003-12-18 | University Of Minnesota, A Minnesota Corporation | Compositions for producing factor Xa |
| EP1853926A2 (en) * | 2005-02-16 | 2007-11-14 | The Board Of Trustees Of The University Of Illinois | Procoagulants based on metal-chelating lipids |
| EP1869082B1 (en) * | 2005-03-04 | 2011-04-13 | The Board Of Trustees Of The University Of Illinois | Coagulation and fibrinolytic cascades modulator |
| WO2009046194A2 (en) * | 2007-10-05 | 2009-04-09 | The Board Of Trustees Of The University Of Illinois | Fibrin sealant |
| WO2009061697A1 (en) | 2007-11-09 | 2009-05-14 | The Board Of Trustees Of The University Of Illinois | Anticoagulant antagonist and hemophilia procoagulant |
| US8372343B2 (en) * | 2007-12-07 | 2013-02-12 | Sheldon Goldstein | Multiple coagulation test cartridge and method of using same |
| JP5355588B2 (ja) | 2007-12-20 | 2013-11-27 | ノバルティス アーゲー | コンタクトレンズを製造する方法 |
| EP3291208B1 (en) | 2016-08-31 | 2020-09-30 | Ricoh Company, Ltd. | Hydrogel structure, blood vessel, internal organ model, practice tool for medical procedure, and method of manufacturing the hydrogel structure |
| US10429377B1 (en) | 2019-03-15 | 2019-10-01 | Coagulation Sciences Llc | Coagulation test device, system, and method of use |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3785772A (en) * | 1971-12-08 | 1974-01-15 | Blowitz M | Blood analyzer |
| WO1980002805A1 (en) * | 1979-06-11 | 1980-12-24 | Gambro Ab | Process for the treating of and/or removal of substances from a liquid,especially whole blood,and a device and a membrane for the realization of said process |
| US4452682A (en) * | 1980-10-24 | 1984-06-05 | Hitachi, Ltd. | Apparatus for measuring clinical emergency check items of blood |
| DE3311287A1 (de) * | 1983-03-28 | 1984-10-04 | Behringwerke Ag, 3550 Marburg | Verfahren zur fotometrischen bestimmung der aktivierten partiellen thromboplastinzeit und reagenz dazu |
| US4604182A (en) * | 1983-08-15 | 1986-08-05 | E. I. Du Pont De Nemours And Company | Perfluorosulfonic acid polymer-coated indicator electrodes |
-
1988
- 1988-02-08 US US07/154,083 patent/US4865984A/en not_active Expired - Fee Related
-
1989
- 1989-02-01 JP JP1502293A patent/JP2756606B2/ja not_active Expired - Lifetime
- 1989-02-01 AU AU30604/89A patent/AU607661B2/en not_active Ceased
- 1989-02-01 WO PCT/US1989/000397 patent/WO1989007133A2/en active IP Right Grant
- 1989-02-01 EP EP89902462A patent/EP0353291B1/en not_active Expired - Lifetime
- 1989-02-07 CA CA000590377A patent/CA1282361C/en not_active Expired - Fee Related
- 1989-09-21 FI FI894472A patent/FI90254C/sv not_active IP Right Cessation
- 1989-10-06 DK DK494989A patent/DK494989A/da not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| DK494989A (da) | 1989-12-07 |
| CA1282361C (en) | 1991-04-02 |
| WO1989007133A2 (en) | 1989-08-10 |
| EP0353291A1 (en) | 1990-02-07 |
| FI894472A0 (sv) | 1989-09-21 |
| FI894472A (sv) | 1989-09-21 |
| US4865984A (en) | 1989-09-12 |
| JP2756606B2 (ja) | 1998-05-25 |
| JPH02503057A (ja) | 1990-09-27 |
| WO1989007133A3 (en) | 1989-09-08 |
| FI90254C (sv) | 1994-01-10 |
| AU3060489A (en) | 1989-08-25 |
| AU607661B2 (en) | 1991-03-07 |
| EP0353291B1 (en) | 1993-01-27 |
| DK494989D0 (da) | 1989-10-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FI90254B (sv) | Dynamisk enzymreaktor med kontinuerlig flöde | |
| JP7250744B2 (ja) | 凝固分析を使用した抗凝固剤の検出および分類 | |
| Funk et al. | Reptilase®‐R—A New Reagent in Blood Coagulation | |
| US8802386B2 (en) | Diagnostic test for determining the concentration of transient proteolytic activity in composite biological media | |
| US8551405B2 (en) | Electrophoretic interactive spectral methods and devices for the detection and/or characterization of biological particles | |
| JPH10500008A (ja) | 乾燥プロトロンビン時間アッセイ | |
| Zeibi Shirejini et al. | Current and future strategies to monitor and manage coagulation in ECMO patients | |
| Ząbczyk et al. | Assays of fibrin network properties altered by VKAs in atrial fibrillation–importance of using an appropriate coagulation trigger | |
| Rasi et al. | Plasma β-thromboglobulin in acute myocardial infarction | |
| WO1989008150A1 (en) | Method for measuring biological activity of antithrombin iii and reagents for the measurement | |
| JP5212821B2 (ja) | スペーサーを介して高分子へ結合する基質を含む修飾基質を用いた酵素測定アッセイ | |
| US5627038A (en) | Factor IX chromogenic assay | |
| JP5176085B2 (ja) | プロテインｓ及びプロテインｃの活性測定方法並びに活性測定試薬 | |
| JP2009198506A (ja) | 血液凝固反応抑制血漿タンパク質の活性測定方法及び活性測定試薬 | |
| WO2009046274A1 (en) | Methods of detection of factor xia and tissue factor | |
| NO176574B (no) | Dynamisk kontinuerlig strömmende enzymreaktor | |
| Quien et al. | Plasma tissue factor antigen levels in capillary whole blood and venous blood: effect of tissue factor on prothrombin time | |
| Owens et al. | Ethanol inhibition of thrombus formation on collagen-coated glass | |
| US5114845A (en) | Assays for plasminogen activator inhibitor and soluble fibrin | |
| Tang et al. | Preliminary study of simultaneous multi-anticoagulant deficiency diagnosis by fiber optic multi-analyte biosensor | |
| EP0040601B1 (en) | Method for detecting proteolytic enzymes in blood | |
| RU2160448C2 (ru) | Способ определения фибринолитической активности мочи | |
| RU2222019C2 (ru) | Способ контроля лечения непрямыми антикоагулянтами | |
| KOTLAREK | Optical biosensing of biomarkers in blood and plasma enabled by biocompatible polymer architectures | |
| JPWO2012124798A1 (ja) | 試料中の総プロテインｓの活性測定試薬及び活性測定方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| BB | Publication of examined application | ||
| MM | Patent lapsed | ||
| MM | Patent lapsed |
Owner name: MOUNT SINAI SCHOOL OF MEDICINE OF THE |